Etifoxine

Summary

Etifoxine (CHEMBL2106227) is a phase-3 clinical-stage small molecule (ATC N05BX03); indicated across 1 condition including anxiety.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N05BX03
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 300.8 Da · C17H17ClN2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106227
Name	Etifoxine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135413553
ATC	N05BX03
Molecular formula	C17H17ClN2O
Molecular weight	300.8
InChIKey	IBYCYJFUEJQSMK-UHFFFAOYSA-N

SMILES: CCN=C1NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3

IUPAC name: 6-chloro-N-ethyl-4-methyl-4-phenyl-1H-3,1-benzoxazin-2-imine

Also known as: Etifoxina, Etifoxine, HOE 36801, HOE-36801, ETIFOXINE, ETIFOXINE (HYDROCHLORIDE), Etifoxine (hydrochloride)

Patent coverage: 181 distinct patent families (585 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 572 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: GABA-A receptor; anion channel.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O09028	5.17	IC50	6700	nM	CHEMBL_ACT_19026742

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02147548	PHASE3	COMPLETED	Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
NCT03850301	Not specified	RECRUITING	Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).